Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously with Hepatitis B Virus Vaccine, Group A Meningococcal Polysaccharide Vaccine, Measles-Rubella Combined Vaccine and Japanese Encephalitis Vaccine: A Multi-Center, Randomized, Controlled Clinical Trial in China

被引:6
|
作者
Liu, Xiaodong [1 ,2 ]
Chang, Shaoying [3 ]
Wang, Ruize [4 ]
Xiao, Yanhui [5 ]
Li, Fangjun [6 ]
Xu, Qing [1 ,2 ]
Zhang, Shaobai [4 ]
Chen, Xiao [3 ]
Zhang, Shangxiao [6 ]
Zhang, Min [5 ]
Chen, Xiaoqi [7 ]
Cao, Qingfan [8 ]
Liu, Xiaoyu [4 ]
Wang, Hui [3 ]
Zhan, Daihong [9 ]
Chen, Haiping [5 ]
Chen, Wei [7 ]
Jiang, Jianyong [10 ]
Zhang, Chao [4 ]
Wang, Haijiao [3 ]
Gao, Lidong [6 ]
Shi, Xuanwen [5 ]
Yang, Xiaoming [5 ]
Xu, Aiqiang [1 ,2 ]
机构
[1] Shandong Prov Ctr Dis Control & Prevent, Jinan 250014, Peoples R China
[2] Shandong Univ, Acad Prevent Med, Jinan 250100, Peoples R China
[3] Shanxi Prov Ctr Dis Control & Prevent, Taiyuan 030012, Peoples R China
[4] Shaanxi Prov Ctr Dis Control & Prevent, Xian 710054, Peoples R China
[5] China Natl Biotec Grp Co Ltd, Beijing 100024, Peoples R China
[6] Hunan Prov Ctr Dis Control & Prevent, Changsha 410005, Peoples R China
[7] Wuhan Inst Biol Prod Co Ltd, Wuhan 430200, Peoples R China
[8] Rushan City Ctr Dis Control & Prevent, Rushan 264500, Peoples R China
[9] Shimen Cty Ctr Dis Control & Prevent, Changde 415300, Peoples R China
[10] Haiyang City Ctr Dis Control & Prevent, Haiyang 265199, Peoples R China
关键词
inactivated enterovirus 71 vaccine; simultaneous administration; hand; foot and mouth disease; separate administration; MOUTH-DISEASE; DOUBLE-BLIND; CHILDREN; EFFICACY; FOOT; HAND; OUTBREAK;
D O I
10.3390/vaccines10060895
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The aim of this study was to investigate the immunogenicity and safety of the enterovirus 71 vaccine (EV71 vaccine) administered alone or simultaneously. Methods: A multi-center, open-label, randomized controlled trial was performed involving 1080 healthy infants aged 6 months or 8 months from Shandong, Shanxi, Shaanxi, and Hunan provinces. These infants were divided into four simultaneous administration groups and EV71 vaccine separate administration group. Blood samples were collected from the infants before the first vaccination and after the completion of the vaccination. This trial was registered in the Clinical Trials Registry (NCT03519568). Results: A total of 895 were included in the per-protocol analysis. The seroconversion rates of antibodies against EV71 in four simultaneous administration groups (98.44% (189/192), 94.57% (122/129), 99.47% (187/188) and 98.45% (190/193)) were non-inferior to EV71 vaccine separate administration group (97.93% [189/193]) respectively. Fever was the most common adverse event, the pairwise comparison tests showed no difference in the incidence rate of solicited, systemic or local adverse events. Three serious adverse events related to the vaccination were reported. Conclusions: The evidence of immunogenicity and safety supports that the EV71 vaccine administered simultaneously with vaccines need to be administered during the same period of time recommended in China.
引用
收藏
页数:11
相关论文
共 48 条
  • [1] Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously With Hepatitis B Vaccine and Group A Meningococcal Polysaccharide Vaccine: A Phase 4, Open-Label, Single-Center, Randomized, Noninferiority Trial
    Zhang, Zewu
    Liang, Zhenglun
    Zeng, Ji
    Zhang, Jikai
    He, Peng
    Su, Jiali
    Zeng, Yaoming
    Fan, Renfeng
    Zhao, Dan
    Ma, Wenjun
    Zeng, Gang
    Zhang, Qiaoli
    Zheng, Huizhen
    JOURNAL OF INFECTIOUS DISEASES, 2019, 220 (03) : 392 - 399
  • [2] Immunogenicity and safety of the inactivated enterovirus 71 vaccine administered concomitantly with the measles-rubella vaccine in infants aged 8 months in China: A noninferiority randomized controlled trial
    Zhao, Zhimei
    Liao, Yuyi
    Li, Yuan
    Jiang, Guorun
    Huang, Zhuhang
    Yang, Huijuan
    Ou, Zhiqiang
    Yin, Qiongzhou
    Chen, Junhu
    Deng, Yan
    Jiang, Ruiju
    Che, Yanchun
    Li, Qihan
    Zheng, Huizhen
    Zhang, Jikai
    VACCINE, 2022, 40 (33) : 4709 - 4715
  • [3] Immunogenicity and safety of an inactivated enterovirus 71 vaccine co-administered with measles-mumps-rubella vaccine and live-attenuated Japanese encephalitis vaccine: a phase 4, single-center, randomized controlled trial
    Liu, Xiaoyu
    Yang, Wanqi
    Zhang, Chao
    Wu, Heng
    Wang, Ruize
    Ding, Qiang
    Hu, Yan
    Xiong, Yongli
    Zhang, Shaobai
    Wang, Lin
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (12) : 5348 - 5354
  • [4] Immunogenicity and safety of an inactivated enterovirus 71 vaccine coadministered with trivalent split-virion inactivated influenza vaccine: A phase 4, multicenter, randomized, controlled trial in China
    Chen, Yaping
    Xiao, Yanhui
    Ye, Ying
    Jiang, Feng
    He, Hanqing
    Luo, Linyun
    Chen, Haiping
    Shi, Lubin
    Mu, Qiuyue
    Chen, Wei
    Guo, Xue
    Zhang, Min
    Li, Jun
    Guan, Qinghu
    Chen, Zhiping
    Yang, Xiaoming
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [5] Safety and Immunogenicity of Enterovirus 71 Vaccine (Vero Cell) Administered Simultaneously with Trivalent Split-Virion Influenza Vaccine in Infants Aged 6-7 Months: A Phase 4, Randomized, Controlled Trial
    Xiao, Yanhui
    Guo, Xue
    Zhang, Min
    Chen, Yaping
    Zhang, Yanyang
    Yu, Xiaoqing
    Luo, Linyun
    Chen, Haiping
    Xu, Weichai
    Liu, Haibo
    Wu, Lixia
    Hou, Renwu
    Ma, Yong
    Long, Lin
    Ruan, Jiewei
    Chen, Wei
    Yang, Xiaoming
    VACCINES, 2023, 11 (04)
  • [6] Immunogenicity and safety of an inactivated COVID-19 vaccine (CoronaVac®) co-administered with an inactivated enterovirus type 71 vaccine (Inlive®): A phase 4, randomized, controlled trial
    Shu, Yajun
    Sun, Zhuoqun
    Gao, Fan
    Huang, Zhuhang
    Meng, Xing
    Chen, Shaomin
    Shu, Qun
    Wang, Lianhao
    Zhang, Hengming
    Ying, Zhifang
    Zhang, Jikai
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [7] Immunogenicity, Safety, and Immune Persistence of a Novel Inactivated Human Enterovirus 71 Vaccine: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
    Li, Yan-Ping
    Liang, Zheng-Lun
    Xia, Jie-Lai
    Wu, Jun-Yu
    Wang, Ling
    Song, Li-Fei
    Mao, Qun-Ying
    Wen, Shu-Qun
    Huang, Ren-Guo
    Hu, Yuan-Sheng
    Yao, Xin
    Miao, Xu
    Wu, Xing
    Li, Rong-Cheng
    Wang, Jun-Zhi
    Yin, Wei-Dong
    JOURNAL OF INFECTIOUS DISEASES, 2014, 209 (01) : 46 - 55
  • [8] Immunogenicity and Safety of Inactivated Enterovirus 71 Vaccine in Children Aged 36-71 Months: A Double-Blind, Randomized, Controlled, Non-inferiority Phase III Trial
    Zhang, Lifen
    Gao, Fan
    Zeng, Gang
    Yang, Haitao
    Zhu, Taotao
    Yang, Shuangmin
    Meng, Xing
    Mao, Qunying
    Liu, Xiaoqiang
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2021, 10 (04) : 440 - 447
  • [9] Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo- controlled, phase 3 trial
    Nguyen, Trong Toan
    Chiu, Cheng-Hsun
    Lin, Chien-Yu
    Chiu, Nan-Chang
    Chen, Po-Yen
    Le, Thi Tuong Vy
    Le, Dang Ngan
    Duong, An Han
    Nguyen, Van Luan
    Huynh, Thi Nguyet
    Truong, Huu Khanh
    Phan, Trong Lan
    Nguyen, Thi Thanh Thao
    Shih, Shin-Ru
    Huang, Chung-Guei
    Weng, Yi-Jen
    Hsieh, Erh-Fang
    Chang, Stanley
    Chen, Charles
    Tai, I-Chen
    Huang, Li-Min
    LANCET, 2022, 399 (10336) : 1708 - 1717
  • [10] Randomized Trial: Immunogenicity and Safety of Coadministered Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine and Combined Hepatitis A and B Vaccine in Girls
    Pedersen, Court
    Breindahl, Morten
    Aggarwal, Naresh
    Berglund, Johan
    Oroszlan, Gyoergy
    Silfverdal, Sven Arne
    Szuts, Peter
    O'Mahony, Michael
    David, Marie-Pierre
    Dobbelaere, Kurt
    Dubin, Gary
    Descamps, Dominique
    JOURNAL OF ADOLESCENT HEALTH, 2012, 50 (01) : 38 - 46